Clinical trials located in

Pistoia

Pistoia city is located in Italy. Currently, 6 clinical trials are being conducted in this city.

Pistoia, nestled in Tuscany, Italy, boasts a rich tapestry of history and culture. Founded in the 2nd century BC, this city is renowned for its well-preserved medieval architecture. The Piazza del Duomo is the heart of Pistoia, surrounded by monumental buildings like the Cathedral of San Zeno, famous for its silver altar. The city’s tradition in nursery gardening has earned it the title “City of Green,” influencing garden designs worldwide. Pistoia also hosts the unique “Giostra dell’Orso,” a medieval jousting tournament, every July, celebrating its vibrant heritage.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Evaluating topical treatment for chronic diabetic foot ulcers

    The study investigates the efficacy of a novel treatment, AUP1602-C, for Diabetic Foot Ulcers (DFUs). Participants are allocated into two groups: one receives standard DFU treatment plus a placebo, while the other receives standard treatment plus AUP1602-C. The dosage of AUP1602-C is based on previous successful trials. The study focuses on safety, tolerability, and effectiveness, monitoring ulcer healing through measurements of area, volume, depth, recurrence, and healing rates. Additionally, patient quality of life is assessed using the EuroQoL-5 Dimensions and Dermatology Life Quality Index questionnaires. The study also tracks hospital visits and medication duration related to DFUs.

    • AUP1602-C
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine
  • The new treatment for solid tumors: the tisotumab vedotin trial

    This clinical trial is studying the effectiveness and safety of a treatment called tisotumab vedotin for patients with solid tumors. The trial is divided into seven parts, each evaluating a different treatment schedule or combination of medications. These treatments may include additional drugs like pembrolizumab and carboplatin. Tumor types are being studied include colorectal cancer, squamous non-small cell lung cancer (sqNSCLC), exocrine pancreatic adenocarcinoma, and squamous cell carcinoma of the head and neck (SCCHN). Participants must be over 18 years old and must have experienced disease progression after their most recent treatment. The primary goal of the trial is to assess the effectiveness of tisotumab vedotin, either alone or in combination with other agents.

    • Tisotumab vedotin
    • Carboplatin
    • Cisplatin
    • Pembrolizumab

See more clinical trials in other cities in Italy:

.